


SEP 11 2002  
AUG 26 2002

DT05 Rec'd PCT/PTO 26 AUG 2002  
PATENTS

MAIL CERTIFICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on August 19, 2002

  
Bruce S. Londa

RECEIVED

SEP 25 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Atty's Docket No.: 101195-54

COPY OF PAPERS  
ORIGINALLY FILED

GROUP ART UNIT : 1642

APPLICANT : Bernd Dörken et al.

APPLN. NUMBER : 09/869,508

FILED : June 5, 2002

FOR : Gene Transfer Vector for the Diagnosis and Therapy of Malign Tumors

REQUEST FOR CORRECTION OF FILING RECEIPT

Hon. Assistant Commissioner of Patents  
Washington, D.C. 20231


ATTENTION: Customer Correction Branch  
Application Processing Division

Sir:

We are returning herewith the filing receipt prepared for the above identified patent application. We would like to respectfully point out that all of the inventors were not included in the filing receipt. A copy of the declaration filed with this application is enclosed.

Please issue a corrected filing receipt.

Respectfully Submitted,

  
Bruce S. Londa (33,531)  
Attorney for Applicant  
Norris, McLaughlin & Marcus P.A.  
220 East 42<sup>nd</sup> Street, 30<sup>th</sup> Floor  
New York, N.Y. 10017  
Telephone: (212)808-0700  
Facsimile: (212)808-0844



## UNITED STATES PATENT AND TRADEMARK OFFICE

COPY OF PAPERS  
ORIGINAL FILEDCOMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/869,508	06/05/2002	1642	625	101195-54	4	10	1

CONFIRMATION NO. 4142

27387  
BRUCE LONDA  
NORRIS, MCLAUGHLIN & MARCUS, P.A.  
220 EAST 42ND STREET, 30TH FLOOR  
NEW YORK, NY 10017

RECEIVED

SEP 25 2002

## FILING RECEIPT



\*OC000000008482626\*

TECH CENTER 1600/2900

Date Mailed: 07/30/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Bernd Dorken, Berlin, GERMANY;  
Gerhard Wolff, Glichicle, GERMANY;  
Hans- Dieter Royer, Dusseccdorf, GERMANY;  
*Christiane WoiSchwill, Berlin, Germany*  
*Martin Janz, Berlin, Germany*  
*Axel Schumacher, Berlin, Germany*

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/DE99/04099 12/27/1999

## Foreign Applications

GERMANY 19860602.8 12/29/1998

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

## Title

Gene transfer vector for the diagnosis and therapy of malign tumors

---

**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulation, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a security order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).